CRISPR Therapeutics (CRSP) Misses Q1 EPS by 37c

CRISPR Therapeutics (NASDAQ: CRSP) reported Q1 EPS of ($1.58), $0.37 worse than the analyst estimate of ($1.21). Revenue for the quarter came in at $860 thousand versus the consensus estimate of $7.1 million.

For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.

You May Also Be Interested In

• Anthropic plans IPO potentially exceeding SpaceX's $86B record - Bloomberg
• Exchange Bank declares Q3 dividend, CEO to retire in 2027
• Blue Owl Capital (OWL) spreader of 50K contracts of August 12 and November 11 puts as share price down 2%